Claim OwnershipHealthcare Unfiltered
Subscribed: 67Played: 2,405
Subscribe
© 2025 Healthcare Unfiltered
Description
Healthcare Unfiltered is an honest, raw, timely podcast tackling any and all topics in healthcare that affect stakeholders. Dr. Chadi Nabhan uses his dynamic conversational skills to challenge his guests to address controversial and important topics. He also brings on world renowned experts to discuss clinical advances in medicine.
256 Episodes
Reverse
Journalist Erin O’Hearn joins Chadi to share her deeply personal story as both a patient and a caregiver navigating the healthcare system for more than two decades. Drawing from her lived experiences, Erin reflects on how today’s advances in artificial intelligence could have supported her journey—easing the emotional and logistical burdens of care while improving communication and empathy between patients and providers. She offers a thoughtful and forward-looking take on the MAHA movement, a...
Chadi sits down with Dr. Debra Patt, Executive Vice President of Texas Oncology and President of the Community Oncology Alliance (COA), for an in-depth conversation about the evolving landscape of community oncology. Dr. Patt outlines her vision for bringing innovation and artificial intelligence into routine cancer care—addressing challenges from clinical decision-making to physician burnout—while ensuring equitable access to cutting-edge treatments across all practice settings. She also dis...
Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies...
Dr. Estelamari Rodriguez, thoracic oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, joins the show to break down the latest advances in non-mutation driven and small cell lung cancer presented at the World Conference on Lung Cancer (WCLC) and how they translate into everyday clinical practice. She discusses pivotal studies including the ALCHEMIST trial exploring adjuvant therapy in ALK-fusion–positive early-stage lung cancer, PACIFIC-2 assessing concurrent immuno...
Returning guest Dr. Amer Zeidan of Yale Medicine and Smilow Cancer Hospital joins to discuss how clinicians should approach low-risk Myelodysplastic Syndrome (MDS), which is most often managed in community settings. He breaks down how to risk-stratify patients using molecular and prognostic markers, when to treat versus observe, and his preferred first-line therapies in today’s landscape. Dr. Zeidan also delves into the COMMANDS trial and the role of luspatercept, emerging questions shaping t...
Returning guest Jill Feldman, a prominent lung cancer survivor and patient advocate, shares her reflections on the World Conference on Lung Cancer (WCLC) from a patient’s point of view. She discusses how patients and advocates interpret complex scientific data, why attending conferences like WCLC is vital for bridging the gap between research and real-world experience, and how the dialogue between scientists and patients continues to evolve. Jill also highlights key takeaways from the meeting...
Investigative journalist and New York Times bestselling author Gardiner Harris joins the podcast to dive deep into his groundbreaking book, “No More Tears: The Dark Secrets of Johnson & Johnson.” Harris recounts the extensive research and challenges behind uncovering how J&J—long regarded as a trusted “goliath” of American healthcare—played a far greater role in fueling the opioid epidemic than Purdue Pharma, a contribution he argues led to more than two million American deaths yet re...
Returning guest Anthony DiGiorgio, DO, a practicing neurosurgeon at UCSF and noted health policy commentator, takes a deep dive into the 340B Drug Pricing Program—one of the most consequential yet misunderstood mechanisms in US healthcare. He traces the program’s origins in the early 1990s, designed to help safety net hospitals stretch scarce federal resources to better serve vulnerable patients. Dr. DiGiorgio examines how, over time, many institutions have leveraged 340B as an ancillary reve...
Dr. Anand Patel, DO, founder of LV8 Health, walks us through the philosophy and mechanics of concierge-style longevity medicine. He explains how LV8 applies Medicine 3.0, combining precision diagnostics (DEXA, VO₂ max, resting metabolic rate, advanced blood panels) with regenerative and geroprotective therapies, nutrition, fitness, and sleep optimization. You’ll hear how he translates data from wearables and diagnostics into bespoke plans, how he helps patients sustain behavior change, and ho...
Gavin MacBeath, CEO of TScan Therapeutics, takes us inside his journey from scientist to biotech leader and what it means to build and run a therapeutic development company at the cutting edge of immuno-oncology. He breaks down how TScan’s platform works to discover and match T-cell receptors (TCRs) with their antigens, and why TCR-T therapies may provide distinct benefits over CAR-T approaches, especially when tackling solid tumors. He also discusses which diseases are most likely to respond...
Dr. Sameer Keole, radiation oncologist at Mayo Clinic Arizona and president of ASTRO, joins the show to preview the upcoming ASTRO Annual Meeting and its key themes. He reflects on his presidential term, discussing accomplishments, lessons learned, and initiatives like his “defense to offense” vision and community outreach efforts. Dr. Keole also tackles hot-button topics in radiation oncology, including the evolving roles of proton therapy and artificial intelligence in patient care. Check o...
In this follow-up episode, Dr. Ed Livingston—renowned surgeon, educator, researcher, and former deputy editor at JAMA—returns to discuss the latest developments in his ongoing legal battle. He reflects on what has transpired in the three months since his last appearance, offering insights into the discovery process and the legal details shaping the case as it heads toward a July 2026 trial date.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan...
Dr. Douglas Flora, Executive Medical Director of Oncology Services at St. Elizabeth Healthcare Cancer Center and Editor-in-Chief of the journal AI in Precision Oncology, shares his pragmatic perspective on how AI is reshaping cancer care today and tomorrow. He discusses real-world applications such as FDA-approved pattern recognition tools in imaging and pathology, how AI may soon integrate with ctDNA to guide treatment decisions, and the clinical trials needed to advance this field. Dr. Flor...
Dr. Monique Diaz, Chief Medical Informatics Officer at CommonSpirit Health, unpacks the intersection of big data, clinical care, and healthcare innovation. She shares how informatics transforms resource allocation, patient engagement, and system efficiency—while offering a behind-the-scenes look at the daily responsibilities of a CMIO, from EMR coding to AI integration. Dr. Diaz also explores the evolving relationship between informatics and AI, and how future advancements hinge on ethical fr...
Dr. Sandy Scheinbaum, founder of the Functional Medicine Coaching Academy, joins the show to break down the principles of functional medicine—a patient-centered approach that integrates lifestyle, nutrition, psychology, and mind-body practices to address the root causes of illness. She shares how her academy trains coaches to guide individuals through sustainable behavior change, explains how mental and emotional states can directly impact physical symptoms, and discusses why functional medic...
Dr. Anthony DiGiorgio, a neurosurgeon at UCSF with a strong interest in healthcare policy, joins the show to unpack the complex and often misunderstood world of Medicaid. In a wide-ranging and nuanced discussion, he explores who qualifies for coverage, why most Medicaid spending goes to groups people don’t typically expect, and whether the system should be expanded or fundamentally reformed. Dr. DiGiorgio outlines his support for a robust safety net, emphasizing targeted subsidies over a gove...
Dr. Ed Livingston, renowned surgeon, educator, and researcher, who was a former deputy editor at JAMA, found himself out of a job after a JAMA podcast he hosted with Dr. Mitch Katz that discussed, among other items, structural racism as a contributor to the high mortality in minorities from COVID. This incident led to a series of lawsuits, some of which were highly publicized.Ed shares behind the scenes events, incidents, and what transpired in 2021, and how the AMA handled the situation. In ...
Ben Casavant, co-founder and CEO of Tasso, joins the show to discuss how he transformed the idea of patient-led blood collection into a reality through devices like Tasso+. He explains how Tasso’s self-collection kits—designed to be easy, virtually painless, and used anytime at home—solve the scalability issues of mobile phlebotomy while improving patient convenience, adherence, and access to care. Casavant also details the company’s growth journey, its FDA-cleared and CE-marked products, the...
Dr. Pallawi Torka of Memorial Sloan Kettering Cancer Center joins to share highlights from ASCO and EHA 2025 on the evolving landscape of B-cell lymphomas, including Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. She offers in-depth insights on the STARGLO study and its recent ODAC review, the POLARGO trial, a rare T-cell leukemia (T-LGL) study, and new data supporting nivolumab-AVD in frontline Hodgkin lymphoma. Additional discussion includes the inMIND tri...
Dr. Ben Derman of the University of Chicago Medicine joins the show to unpack major updates in multiple myeloma presented at ASCO and EHA 2025. He discusses the growing role of quadruple therapy across all patient populations and its implications for the future of autologous stem cell transplant, including insights from the MIDAS trial on MRD-guided transplant decisions. Additional highlights include MRD-negativity as a potential off-ramp for maintenance therapy, evolving data from frontline ...
Comments
Download from Google Play
Download from App Store
United States